Work

Phase I dose escalation of LAVA-051, a novel bispecific gamma-delta T-cell engager (Gammabody), in relapsed/refractory hematological malignancies.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2577

Authors: Annemiek Broijl, Niels W.C.J. van de Donk, Francesc Bosch, Maria-Victoria Mateos, Paula Rodríguez-Otero, Alessandra Tucci, Paolo Ghia, Anton EP Adang, Paul WHI Parren, Ilse Tuinhof, Sanjana Umarale, Benjamin Winograd, Hans J. van der Vliet, Arnon P. Kater

Institutions: Erasmus MC Cancer Institute, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Vall d'Hebron Hospital Universitari, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Clinica Universidad de Navarra, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, Lava Therapeutics (Netherlands), Amsterdam University Medical Centers

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286298894

Cites:

Cited by: 8

Related to: 10